MaaT provides a business update, which reiterated the company's progress with respect to its pipeline, and following the previously announced EU regulatory submission for MaaT013 in aGvHD, the company continues to search for a commercialisation partner in Europe ahead of a potential approval in 2H26. Timeline for MaaT013 US trial launch shifts to 2026 (from 4Q25) to focus resources on the European opportunity. Looking ahead, data updates for MaaT013 in aGvHD (final results incl. 12-month OS), as...
Feedback of the companies present at the ODDO BHF Nextcap Forum Company Country Market cap. (m) Company Country Market cap. (m) Accsys Technologies € 124 Hoffmann Green € 62 Afyren € 72 Hornbach € 1 451 Altri € 1 058 IDI € 537 AMG € 550 Implenia CHF 973 AmRest PLN 3 544 Jacquet Metals € 494 Arcure € 29 Kloeckner & Co € 653 Arverne 194 Knaustabbert € 144 Austriacard Holdings € 188 Lna Santé € 270 Bastide € 218 Medincell € 398 Befesa € 1 116 Nacon € 63 CAF € 1 649 N...
Our 14th edition of the ODDO BHF Nextcap Forum took place on 11 June in Paris, and on 12 June virtually. 96 companies and 170 investors were present for more than 700 meetings organized. Overall, we noted a still cautious tone from companies, with limited visibility on a solid rebound in a persistently uncertain market environment (geopolitical situation, US politics, etc.), even if there are some signs of recovery and certain sectors remain very well positioned (leisure, energy, defence). At th...
MaaT reported updated early access program (EAP) results for MaaT013 (microbiome therapy, enema formulation) in aGvHD at EHA, being held 12-15 June. The data, which was previously shared in the abstract last month, shows that the response rates and overall survival observed in the steroid refractory and ruxulitinib resistant subset of patients (n=70) are in line with what was observed in the phase 3 ARES trial. In our view, this points to the consistency of outcomes with MaaT013 in this patient ...
MaaT announced the submission of the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its lead drug candidate MaaT013 (microbiome therapy, enema formulation) in aGvHD under the brand name Xervyteg. Potential approval could be granted in 2H26, and MaaT is actively exploring strategic partnerships to commercialise MaaT013 in Europe. We believe the solid phase 3 results and good uptake in the early access program will be supportive of MaaT013's commercial launch ...
RUBIS: Evolutions at the Supervisory Board and its Committees - Communication following the requests received for the inclusion of resolutions to the agenda of the Shareholders’ Meeting of 12 June 2025 Paris, 22 May 2025, 7:45am 1. The Supervisory Board announces the cooptation of Antoine Sautenet and reorganises its specialised Committees following Nils Christian Bergene's departure Following Nils Christian Bergene's departure on 15 May 2025, the Supervisory Board decided at its meeting on 21 May 2025, upon the Compensation, Appointments and Governance Committee’s recommendation, to coo...
RUBIS: Évolutions au sein du Conseil de Surveillance et de ses Comités - Communication relative aux demandes reçues d’inscription de résolutions à l’ordre du jour de l’Assemblée Générale du 12 juin 2025 Paris, le 22 mai 2025, 7h45 1. Le Conseil de Surveillance annonce la cooptation de M. Antoine Sautenet et procède à une recomposition au sein de ses Comités spécialisés suite à la démission de M. Nils Christian Bergene Compte tenu de la démission de M. Nils Christian Bergene le 15 mai 2025, le Conseil de Surveillance a décidé lors de sa réunion du 21 mai 2025, sur proposition du Comité Ré...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.